Atlas Trials

Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib

Clinical trial NCT07396454 · RECRUITING

Trial details

NCT number
NCT07396454
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-Negative Breast Cancer
Start date
2026-02-10
Primary completion
2028-06-01
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.